Assessment of Severity and Hydroxyurea Therapy in Sickle Cell Disease

Practical Management of Haemoglobinopathies

Volumn , Issue , 2007, Pages 162-168

  Okpala, Iheanyi E ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Alpha thalassaemia; Beta globin gene haplotype; Haemoglobin genotype; Hydroxyurea therapy; Sickle cell disease (SCD)

Indexed keywords

EID: 84952325076     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988398.ch18     Document Type: Chapter

References (37)

1. Serjeant GR. Sickle cell disease. Lancet 1997; 350: 725-30.
2. Steinberg MH, Hebbel RP. Clinical diversity of sickle cell anemia: genetic and cellular modulation of disease severity. Am J Haematol 1983; 14: 405-16.
3. Okpala IE. The management of crisis in sickle cell disease [review]. Eur J Haematol 1998; 60: 1-6.
4. Charache S. Experimental therapy (of sickle cell disease). Hematol Oncol Clin NorthAm 1996; 10: 1373-82.
5. Powars DR, Meiselman HJ, Fisher TC, Hiti A, Johnson C. Beta-S gene cluster haplotypes modulate haematologic and haemorheologic expression in sickle cell anemia. Am J Pediatr Hematol Oncol 1994; 16: 55-61.
6. Embury SH, Dozy AM, Miller J et al. Concurrent sickle cell anaemia and alpha-thalassaemia. Effect on severity of anemia. N Engl J Med 1982; 306: 270-4.
7. Anyaegbu CC, Okpala IE, Aken'Ova AY, Salimonu LS. Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia. Eur J Haematol 1998; 60: 267-8.
8. Okpala IE, Daniel Y, Haynes R, Odoemene D, Goldman JM. Relationship between the clinical manifestations of sickle cell disease and the expression of adhesion molecules on white blood cells. Eur J Haematol 2002; 69: 135-4.
9. Anyaegbu CC, Okpala IE, Aken'Ova AY, Salimonu LS. Complement haemolytic activity, circulating immune complexes and the morbidity of sickle cell anaemia. APMIS 1999; 107: 699-702.
10. Hedo CC, Okpala IE, Aken'Ova AY, Salimonu LS. Correlates of severity in sickle cell anaemia. Blood 1996; 88 (Suppl): 17b.
11. Hedo CC, Aken'Ova AY, Okpala IE, Durojaiye AO, Salimonu LS. Acute phase reactants and the severity of homozygous sickle cell anaemia. J Intern Med 1993; 233: 467-70.
12. Clarkson JG. The ocular manifestations of sickle cell disease: a prevalence and natural history study. Trans Am OphthalmolSoc 1992; 90: 481-504.
13. Charache S. Eye disease in sickling disorders. Hematol Oncol Clin North Am 1996; 10: 1357-62.
14. Gilman JG, Huisman TH. DNA sequence variation associated with elevated fetal Gg-globin production. Blood 1985; 66: 783-7.
15. Nagel RL, Fabry ME, Pagnier J et al. Haematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegalese and the Benin type. N Engl J Med 1984; 312: 880-4.
16. Labie D, Srinavas R, Duanda O et al. Haplotypes in tribal Indians bearing the sickle gene: evidence for the unicentric origin of the beta S mutation and the unicentric origin of the tribal populations of India. Hum Biol 1989; 61: 479-91.
17. Thein SL, Craig JE. Genetics of HbF/F cell variance in adults and heterocellular hereditary persistence of fetal hemoglobin. Haemoglobin 1998; 22: 401-14.
18. Steinberg MH, Rodgers GP. Pathophysiology of sickle cell disease: role of genetic and cellular modifiers. Semin Hematol 2001; 38: 229-306.
19. Charache S. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol 1997; 34 (Suppl 3): 15-21.
20. Garner C, Tatu T, Reittie JE et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood 2000; 95: 342-6.
21. Game L, Close J, Stephens P et al. An integrated map of human 6q22.3-q24 including a 3 Mb high-resolution BAC/PAC contig encompassing a QTL for for fetal hemoglobin. Genomics 2000; 64: 264-76.
22. Dover GJ, Smith KD, Chang YC et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992; 80: 816-24.
23. Ohene-Frempong K, Weiner SJ, Sleeper LA et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91: 288-94.
24. Milner PF, Kraus AP, Sebes JI et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 21: 1476-81.
25. Moran MC. Osteonecrosis of the hip in sickle cell hemoglobinopathy (review). Am J Orthop 1995; 24: 18-24.
26. Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease - life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-43.
27. Abboud MR, Laver J, Blau CA. Elevation of neutrophil count after G-CSF therapy leads to vaso-occlusive crisis and acute chest syndrome in a patient with sickle cell anaemia. Blood 1996; 88 (Supp l): 15b.
28. Miller ST, Sleeper LA, Pegalow CH et al. Prediction of adverse outcomes in children with sickle cell disease: a report from the cooperative study (CSSCD). N Engl J Med 2000; 342: 83-9.
29. Essien EM. Platelets and platelet disorders in Africa (review). Baillieres Clin Haematol 1992; 5: 441-56.
30. Okpala IE. Steady-state platelet count and complications of sickle cell disease. Hematol J 2002; 3: 214-15.
31. Frenette PS. Sickle cell vaso-occlusion: multistep and multi cellular paradigm. Curr Opin Hematol 2002; 9: 101-6.
32. Styles LA, Lubin B, Vichinsky E et al. Decrease of very late activation antigen-4 and CD36 expression on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 1997; 89: 2554-9.
33. Hillery CA, Du MC, Wang WC, Scott JP. Hydroxyurea therapy decreases in vitro adhesion of sickle erythrocytes to thrombospondin and laminin. Br J Haematol 2000; 109: 322-7.
34. Taylor JG, Tang DC, Savage SA et al. Variants in the VICAM-1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002; 100: 4303-9.
35. Ferster A, Vermylen C, Cornu G et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996; 88: 1960-4.
36. Kinney TR, Helms RW, O'Branski EE et al. Pediatric Hydroxyurea Group: safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood 1999; 94: 1550-4.
37. Hanft VN, Fruchtman SR, Pickens CV et al. Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood 2000; 95: 3589-93.